Abstract Library

#4074 Clinical, genetic and histopathological characterisation of patients with multiple endocrine neoplasia type 1 in two high complexity hospitals in Medellín, Colombia

Introduction: Limited observational data exist regarding the characterization of patients with Multiple Endocrine Neoplasia Type 1 (MEN-1) in Latin America, particularly in Colombia. This scarcity has led to a reliance on studies that may not precisely depict the actual behaviour of the disease within the population.

Conference:

Presenting Author:

Authors: Roman-Gonzalez A, Gil-Gonzalez M, Pérez-Giraldo E, Agredo Delgado V, Lopez-Montoya V,

Keywords: multiple endocrine neoplasia type 1, neuroendocrine tumor, acromegaly, cushing disease, hyperparathyroidism,

#3922 National registry of pheochromocytomas and paragangliomas in the Colombian territory: Epidemiological insights and clinical profiles

Introduction: Limited epidemiological data exist concerning pheochromocytomas and sympathetic paragangliomas (PPGL) in Latin America, resulting in a reliance on small cohorts and case reports that may not accurately represent the true behavior of these tumors in the population.

Conference:

Presenting Author: Zea Lopera J

Authors: Zea Lopera J, Agredo Delgado V, Román González A, Donado Gómez J, Jiménez C,

Keywords: Pheochromocytoma, paraganglioma, PPGL, neuroendocrine tumor, incidentaloma, clinical presentation,

#3557 Final analysis of Chromogranin A for neuroendocrine tumor diagnosis in Chilean patients: An updated case-control study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous and differ geographically. Serum chromogranin A (CgA) is the most used biomarker for NET diagnosis, with a sensitivity of 63-100% and specificity of 95-98% with a cutoff value of 108 ng/mL. Recent studies worldwide have reported varying frequencies of NET patients with high CGA at diagnosis, suggesting that the cutoff value may differ according to each population.

Conference:

Presenting Author: Muñoz Medel M

Authors: Muñoz Medel M, Cordova Delgado M, Duran D, Pinto M, Bravo M,

Keywords: neuroendocrine, chromogranin a, biomarker,

#3528 Computerized tomography (CT)-based hepatic radiomics phenotypes associate with response to anti-angiogenics in neuroendocrine tumors (NETs): A subanalysis from the phase II TALENT clinical trial

Introduction: The phase II TALENT clinical trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, the role of radiomic predictive biomarkers of response to antiangiogenic drugs remain unknown.

Conference:

Presenting Author: Garcia Alvarez A

Authors: Garcia Alvarez A, Hernando J, Ligero M, Delgado E, Ibrahim T,

Keywords: Lenvatinib, Radiomics,

#2803 Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous, serum chromogranin A (CgA) has a 60-100% of sensitivity and 68-100% of specificity with a cutoff value of 108 ng/mL as a marker for diagnosis of NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Munoz Medel M

Authors: Munoz-Medel M, Cordova Delgado M, Pinto M, Bravo M, Retamal I,

Keywords: Neuroendocrine, Chromogranin A, Biomarker,